Recursion Pharmaceuticals Inc (RXRX) Stock AnalysisRXRXStock AnalysisRecursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology and chemistry to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits, scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate silico hypotheses into validated insights and novel chemistry. Its clinical programs in oncology and rare diseases include REC-617, REC-1245, REC-3565 and REC-4539. Its REC-617 is an orally bioavailable, cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced solid tumors. Its REV102 program targets ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), an enzyme implicated in the pathogenesis of HPP. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Recursion Pharmaceuticals Inc is currently not a strong buy. The stock is priced at $3.34, which is significantly below the analyst price target of $5.50 from Morgan Stanley. However, the company continues to face substantial losses, with a net income of -131 million USD in Q2 2026 and a negative gross margin of -49.82%. The RSI is at 48.008, indicating a neutral momentum. The main risk is the ongoing losses and the need for new product introductions to improve financial performance, as highlighted by recent analyst concerns.